GlassScriptPhysician profile
Firas Baidoun
NPI 1881012607
$860.51
in general payments reported to CMS, 2019-2025
10 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2023: $213 · 2024: $347 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $468 · Food and Beverage: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $467.97 |
| Food and Beverage | $269.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $220.58 | 2024-2025 | |
| Intercept Pharmaceuticals, INC. | $123.13 | 2019 | |
| Janssen Biotech, INC. | $117.92 | 2023 | Darzalex, Carvykti, Tecvayli |
| Pfizer INC. | $98.00 | 2024 | |
| Exelixis INC. | $89.95 | 2024 | |
| Sanofi-Aventis U.S. LLC | $69.99 | 2023 | |
| Novartis Pharmaceuticals Corporation | $61.63 | 2024-2025 | |
| Genentech USA, INC. | $34.41 | 2025 | Lunsumio |
| Alexion Pharmaceuticals, INC. | $24.85 | 2023 | |
| Genmab U.S., INC. | $20.05 | 2025 | Epkinly |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Firas Baidoun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.